The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med1995; 333:1581–7.
2.
AdamsHPJrAdamsRJBrottT. Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke2003; 34:1056–83.
3.
AdamsHPJrBendixenBHKappelleLJ. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Trial of Org 10172 in Acute Stroke Treatment. Stroke1993; 24:35–41.
4.
YamaguchiTMoriEMinematsuK. Japan Alteplase Clinical Trial Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke2006; 37:1810–5.
5.
Toyoda K, Koga M, Naganuma M, for the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) study investigators et al.Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients. General outcomes and prognostic factors from the SAMURAI register. Stroke2009; 40:3591–5.
